Constellation Pharmaceuticals Inc. [CNST] is -51.98% lower this YTD. Is it still time to buy?

Constellation Pharmaceuticals Inc. [NASDAQ: CNST] jumped around 1.6 points on Wednesday, while shares priced at $22.62 at the close of the session, up 7.61%. The company report on October 29, 2020 that Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results.

MANIFEST data update planned for the American Society of Hematology (ASH) meeting in December .

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its third-quarter 2020 financial results. The Company also provided updates on its product candidates CPI-0610 and CPI-0209.

Constellation Pharmaceuticals Inc. stock is now -51.98% down from its year-to-date (YTD) trading value. CNST Stock saw the intraday high of $23.18 and lowest of $20.40 per share. The company’s 52-week high price is 59.49, which means current price is +33.06% above from all time high which was touched on 05/12/20.

Compared to the average trading volume of 550.55K shares, CNST reached a trading volume of 1203780 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Constellation Pharmaceuticals Inc. [CNST]?

Oppenheimer have made an estimate for Constellation Pharmaceuticals Inc. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on September 08, 2020. The new note on the price target was released on July 20, 2020, representing the official price target for Constellation Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $36, while JMP Securities analysts kept a Mkt Perform rating on CNST stock. On May 07, 2020, analysts increased their price target for CNST shares from 50 to 75.

The Average True Range (ATR) for Constellation Pharmaceuticals Inc. is set at 1.69 The Price to Book ratio for the last quarter was 2.43, with the Price to Cash per share for the same quarter was set at 10.32.

How has CNST stock performed recently?

Constellation Pharmaceuticals Inc. [CNST] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.85. With this latest performance, CNST shares dropped by -0.88% in over the last four-week period, additionally sinking by -37.11% over the last 6 months – not to mention a drop of -43.46% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CNST stock in for the last two-week period is set at 54.92, with the RSI for the last a single of trading hit 57.08, and the three-weeks RSI is set at 52.01 for Constellation Pharmaceuticals Inc. [CNST]. The present Moving Average for the last 50 days of trading for this stock 21.84, while it was recorded at 21.45 for the last single week of trading, and 29.27 for the last 200 days.

Constellation Pharmaceuticals Inc. [CNST]: Deeper insight into the fundamentals

Constellation Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.80 and a Current Ratio set at 15.80.

Earnings analysis for Constellation Pharmaceuticals Inc. [CNST]

With the latest financial reports released by the company, Constellation Pharmaceuticals Inc. posted -0.69/share EPS, while the average EPS was predicted by analysts to be reported at -0.69/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CNST.

Insider trade positions for Constellation Pharmaceuticals Inc. [CNST]

There are presently around $1,210 million, in the hands of institutional investors. The top three institutional holders of CNST stocks are: SVENNILSON PETER with ownership of 6,051,376, which is approximately 0% of the company’s market cap and around 0.75% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 4,399,512 shares of the stock with an approximate value of $99.52 million in CNST stocks shares; and AVORO CAPITAL ADVISORS LLC, currently with $96.7 million in CNST stock with ownership of nearly 6.875% of the company’s market capitalization.

78 institutional holders increased their position in Constellation Pharmaceuticals Inc. [NASDAQ:CNST] by around 8,867,858 shares. Additionally, 51 investors decreased positions by around 4,225,800 shares, while 23 investors held positions by with 40,385,939 shares. The mentioned changes placed institutional holdings at 53,479,597 shares, according to the latest SEC report filing. CNST stock had 19 new institutional investments in for a total of 778,967 shares, while 26 institutional investors sold positions of 3,161,615 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download free eBook for 



Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.